High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk or Recurrent Bone and Soft Tissue Sarcomas
- Authors
- Choi, Young Bae; Yi, Eun Sang; Lee, Ji Won; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong Hoe
- Issue Date
- Jul-2016
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Bone and Soft Tissue Sarcoma; Children; High-Dose Chemotherapy; Autologous Stem Cell Transplantation
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.31, no.7, pp 1055 - 1062
- Pages
- 8
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 31
- Number
- 7
- Start Page
- 1055
- End Page
- 1062
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64207
- DOI
- 10.3346/jkms.2016.31.7.1055
- ISSN
- 1011-8934
1598-6357
- Abstract
- Despite increasing evidence that high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) might improve the survival of patients with high-risk or recurrent solid tumors, therapy effectiveness for bone and soft tissue sarcoma treatment remains unclear. This study retrospectively investigated the feasibility and effectiveness of HDCT/auto-SCT for high-risk or recurrent bone and soft tissue sarcoma. A total of 28 patients (18 high-risk and 10 recurrent) underwent single or tandem HDCT/auto-SCT between October 2004 and September 2014. During follow-up of a median 15.3 months, 18 patients exhibited disease progression and 2 died of treatment-related toxicities (1 veno-occlusive disease and 1 sepsis). Overall, 8 patients remained alive and progression-free. The 3-year overall survival (OS) and event-free survival (EFS) rates for all 28 patients were 28.7% and 26.3%, respectively. In the subgroup analysis, OS and EFS rates were higher in patients with complete or partial remission prior to HDCT/auto-SCT than in those with worse responses (OS, 39.1% vs. 0.0%, P=0.002; EFS, 36.8% vs. 0.0%, P < 0.001). Therefore, careful selection of patients who can benefit from HDCT/auto-SCT and maximal effort to reduce tumor burden prior to treatment will be important to achieve favorable outcomes in patients with high-risk or recurrent bone and soft tissue sarcomas.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64207)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.